Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).

标题

Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).

作者

关键词

-

出版物

JOURNAL OF CLINICAL ONCOLOGY

Volume 38, Issue 15_suppl, Pages 3081-3081

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2020-05-25

DOI

10.1200/jco.2020.38.15_suppl.3081